On Sept. 22, 2025, Celltrion said in a regulatory filing in South Korea its U.S. subsidiary has acquired Imclone Systems from Eli Lilly in the United States for $330 million.

In a statement, Celltrion said it aimed to complete the factory acquisition process by year-end in cooperation with its partner.

After upgrades and expansions to the facility, both key products the company sells in the United States and future launches will be shielded early from U.S. tariff exposure.